Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMSCs for Ischemic Stroke
NCT05850208Phase 1Unknown
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Feb 2022
- Primary completion
- Nov 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of autologous bone-marrow mesenchymal stem cells in ischemic stroke (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: National Institutes of Health Stroke Scale at 96 weeks. Status: unknown.
02
Drugs
autologous bone-marrow mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05850208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850208.